A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.

Saved in:
Bibliographic Details
Title: A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Authors: Lopez JS; Drug Development Unit at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK. Electronic address: juanita.lopez@icr.ac.uk., Haefliger S; Inselspital, Bern University Hospital, University of Bern, Department of Medical Oncology, Bern, Switzerland., Plummer R; Newcastle University and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK., Clement PM; UZ Leuven - Department of Oncology, Leuven Cancer Institute - KU Leuven, Leuven, Belgium., Jeffry Evans TR; University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK., Läubli H; Department of Oncology, University Hospital Basel, Basel, Switzerland., Roth P; Department of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland., Kristeleit R; Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK., Brazil L; Guy's Hospital, Cancer Centre, London, UK., Tabatabai G; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls Uninversity Tübingen, Tübingen, Germany., Wick A; Neurology Department, University Clinic Universitätsklinikum, Heidelberg, Germany., Wunderlich B; Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany., Beebe K; GeneCentric Therapeutics Inc., Durham, NC, USA., Eisner JR; GeneCentric Therapeutics Inc., Durham, NC, USA., Lane H; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland., Engelhardt M; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland., Kaindl T; Basilea Pharmaceutica International Ltd, Allschwil, Switzerland. Electronic address: thomas.kaindl@basilea.com., Hau P; Wilhelm Sander NeuroOncology Unit and Department of Neurology - Neurooncology, University Hospital Regensburg, Regensburg, Germany., Hundsberger T; Department of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, Sankt Gallen, Switzerland., Steinbach J; Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Jun 17; Vol. 6 (6), pp. 102165.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102165